Sonia M. Davis

Active 1990–2019

50
Papers
20,121
Citations
49
h-index
50
i10-index

Citations

Citations per year for Sonia M. Davis1991: 2 citations1992: 5 citations1993: 7 citations1994: 6 citations1995: 10 citations1996: 6 citations1997: 2 citations1998: 6 citations1999: 2 citations2000: 18 citations2001: 15 citations2002: 35 citations2003: 35 citations2004: 31 citations2005: 56 citations2006: 185 citations2007: 269 citations2008: 322 citations2009: 282 citations2010: 306 citations2011: 217 citations2012: 204 citations2013: 151 citations2014: 141 citations2015: 131 citations2016: 122 citations2017: 100 citations2018: 136 citations2019: 440 citations2020: 358 citations2021: 324 citations2022: 226 citations2023: 144 citations2024: 251 citations2025: 90 citations2026: 1 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,100 citing papers, 36.2% of this breakdownUnited Kingdom: 533 citing papers, 9.2% of this breakdownCanada: 367 citing papers, 6.3% of this breakdownGermany: 286 citing papers, 4.9% of this breakdownAustralia: 225 citing papers, 3.9% of this breakdownChina: 213 citing papers, 3.7% of this breakdownItaly: 169 citing papers, 2.9% of this breakdownNetherlands: 144 citing papers, 2.5% of this breakdownSpain: 140 citing papers, 2.4% of this breakdownFrance: 126 citing papers, 2.2% of this breakdownJapan: 101 citing papers, 1.8% of this breakdownSwitzerland: 100 citing papers, 1.7% of this breakdown
0%36.2%Other 22.3%

Fields

  • Medicine64.4%
  • Neuroscience16.7%
  • Biochemistry, Genetics and Molecular Biology6.6%
  • Psychology5.9%
  • Health Professions2.4%
  • Pharmacology, Toxicology and Pharmaceutics0.9%
  • Other3.1%

Topics

  • Schizophrenia research and treatment13.7%
  • Treatment of Major Depression3.9%
  • Dementia and Cognitive Impairment Research3.8%
  • Tryptophan and brain disorders3.7%
  • Bipolar Disorder and Treatment3.1%
  • Mental Health and Psychiatry2.2%
  • Other69.6%

Coauthors

All papers

Open in search
  1. Associations Between Midlife Vascular Risk Factors and 25-Year Incident Dementia in the Atherosclerosis Risk in Communities (ARIC) Cohort

    Authors: , , , , , , , , , , , , , - JAMA Neurology 2017 cited by 633

  2. Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia

    Authors: , , , , , , , , , , , - New England Journal of Medicine 2005 cited by 5,895

  3. Vagus Nerve Stimulation for Treatment-Resistant Depression: A Randomized, Controlled Acute Phase Trial

    Authors: , , , , , , , , , , , , , , , - Insecta mundi 2005 cited by 686

  4. Effectiveness of Atypical Antipsychotic Drugs in Patients with Alzheimer's Disease

    Authors: , , , , , , , , , , , , - New England Journal of Medicine 2006 cited by 1,198

  5. Gender differences in chronic major and double depression

    Authors: , , , , , , , , , , , - Journal of Affective Disorders 2000 cited by 501

  6. Effectiveness of Clozapine Versus Olanzapine, Quetiapine, and Risperidone in Patients With Chronic Schizophrenia Who Did Not Respond to Prior Atypical Antipsychotic Treatment

    Authors: , , , , , , , , , , , , - American Journal of Psychiatry 2006 cited by 755

  7. Effects of 12 Months of Vagus Nerve Stimulation in Treatment-Resistant Depression: A Naturalistic Study

    Authors: , , , , , , , , , , , , , , , , - Biological Psychiatry 2005 cited by 395

  8. A One-Year Comparison of Vagus Nerve Stimulation with Treatment as Usual for Treatment-Resistant Depression

    Authors: , , , , , , , , , , , , , , , - Biological Psychiatry 2005 cited by 372

  9. Factors associated with early outcomes following standardised therapy in children with ulcerative colitis (PROTECT): a multicentre inception cohort study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Margaret H. Collins, Suresh Venkateswaran, Marla Dubinsky, Vin Tangpricha, Krista Spada, Ashley Britt, Bradley Saul, Nathan Gotman, Jessie Wang, José Serrano, Subra Kugathasan, Thomas Walters, Lee A. Denson - ˜The œLancet. Gastroenterology & hepatology 2017 cited by 100

  10. Prevalence of the metabolic syndrome in patients with schizophrenia: Baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III

    Authors: , , , , , , , , , - Schizophrenia Research 2005 cited by 1,139

  11. Gender Differences in Treatment Response to Sertraline Versus Imipramine in Chronic Depression

    Authors: , , , , , , , , , - American Journal of Psychiatry 2000 cited by 707

  12. Cardiovascular health among diverse Hispanics/Latinos: Hispanic Community Health Study/Study of Latinos (HCHS/SOL) results

    Authors: , , , , , , , , , , , , - American Heart Journal 2016 cited by 97

  13. A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls

    Authors: , , , , , , , , , , - Schizophrenia Research 2005 cited by 531

  14. Neurocognitive Function Among Middle-aged and Older Hispanic/Latinos: Results from the Hispanic Community Health Study/Study of Latinos

    Authors: , , , , , , , , , , - Archives of Clinical Neuropsychology 2014 cited by 118

  15. MSQ: Migraine-Specific Quality-of-Life Questionnaire

    Authors: , , , , - PharmacoEconomics 1998 cited by 95

  16. Clinical Symptom Responses to Atypical Antipsychotic Medications in Alzheimer’s Disease: Phase 1 Outcomes From the CATIE-AD Effectiveness Trial

    Authors: , , , , , , , , , , - American Journal of Psychiatry 2008 cited by 317

  17. Physical Activity Levels in U.S. Latino/Hispanic Adults

    Authors: , , , , , , , , , , , - American Journal of Preventive Medicine 2015 cited by 168

  18. A randomized feasibility pilot trial of hearing treatment for reducing cognitive decline: Results from the Aging and Cognitive Health Evaluation in Elders Pilot Study

    Authors: , , , , , , , , , , , , , , , , , - Alzheimer s & Dementia Translational Research & Clinical Interventions 2017 cited by 106

  19. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: Data from the CATIE schizophrenia trial sample at baseline

    Authors: , , , , , , - Schizophrenia Research 2006 cited by 558

  20. Baseline Neurocognitive Deficits in the CATIE Schizophrenia Trial

    Authors: , , , , , , , , , , , , , , , , , , - Neuropsychopharmacology 2006 cited by 469

  21. Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: Prospective data from phase 1

    Authors: , , , , , , , , , , , - Schizophrenia Research 2008 cited by 287

  22. Machismo, marianismo, and negative cognitive-emotional factors: Findings from the Hispanic Community Health Study/Study of Latinos Sociocultural Ancillary Study.

    Authors: , , , , , , , , , , , - Journal of Latina/o Psychology 2015 cited by 274

  23. Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial

    Authors: , , , , , , , , , , - Schizophrenia Research 2005 cited by 156

  24. Results of phase 3 of the CATIE schizophrenia trial

    Authors: , , , , , , , , - Schizophrenia Research 2008 cited by 142